Abcam, ab249429, Anti-LDLC antibody [EPR10896] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal LDLC antibody. Carrier free. Suitable for IHC-P, WB and reacts with Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR10896,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:WB, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab249429 is the carrier-free version of
ab167416
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
LDLC also known as Low-Density Lipoprotein Cholesterol is a significant component of the plasma lipid transport system. It plays a mechanical role in transporting cholesterol to peripheral tissues. The molecular mass of LDLC varies depending on the size of the lipoprotein particles typically ranging from 2000 to 3000 kDa. LDLC prominently circulates in the blood and is widely expressed throughout the body particularly in liver and intestines where it is synthesized and secreted.
Biological function summary
LDLC serves as the primary cholesterol carrier and is essential for cellular membrane synthesis and maintenance. It forms a complex with apolipoproteins such as ApoB-100 which facilitate interaction with LDL receptors on cell surfaces. This interaction enables the uptake of cholesterol for use in intracellular processes. LDL particles derive from very low-density lipoproteins (VLDL) following triglyceride depletion emphasizing their role in lipid metabolism.
Pathways
The cholesterol transport and lipid metabolism pathways involve LDLC as a core component. One important pathway is the mevalonate pathway where it links to biosynthesis of cholesterol steroids and isoprenoids. The protein SREBP (Sterol Regulatory Element Binding Protein) regulates the expression of LDL receptors impacting cholesterol uptake efficiency. Another relevant pathway is the reverse cholesterol transport pathway involving ApoA-I where excess cholesterol from tissues returns to the liver for excretion.
LDLC is strongly associated with cardiovascular diseases especially atherosclerosis. Elevated levels of LDLC contribute to plaque formation in arterial walls leading to heart diseases. Familial hypercholesterolemia a genetic disorder also links to increased LDLC levels due to defective LDL receptors caused by mutations in the LDLR gene. Apolipoprotein E (ApoE) polymorphisms further affect the clearance rate of LDLC influencing susceptibility to these conditions.